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Anti-cytokine autoantibodies (ACAAs) have been described in a growing number of pri-
mary immunodeficiencies with autoimmune features, including autoimmune polyendo-
crine syndrome type I (APS-1), a prototypical disease of defective T cell-mediated central 
tolerance. Whether defects in peripheral tolerance lead to similar ACAAs is unknown. 
Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) is caused by 
mutations in FOXP3, a master regulator of T  regulatory cells (Treg), and consequently 
results in defective T  cell-mediated peripheral tolerance. Unique autoantibodies have 
previously been described in IPEX. To test the hypothesis that ACAAs are present in 
IPEX, we designed and fabricated antigen microarrays. We discovered elevated levels 
of IgG ACAAs against interferon-α (IFN-α) in a cohort of IPEX patients. Serum from IPEX 
patients blocked IFN-α signaling in vitro and blocking activity was tightly correlated with 
ACAA titer. To show that blocking activity was mediated by IgG and not other serum 
factors, we purified IgG and showed that blocking activity was contained entirely in the 
immunoglobulin fraction. We also screened for ACAAs against IFN-α in a second geo-
graphically distinct cohort. In these samples, ACAAs against IFN-α were elevated in a 
post hoc analysis. In summary, we report the discovery of ACAAs against IFN-α in IPEX, 
an experiment of nature demonstrating the important role of peripheral T cell tolerance.
Keywords: anti-cytokine autoantibodies, interferon-alpha, immunodysregulation polyendocrinopathy enteropathy 
X-linked, autoimmune polyendocrine syndrome type i, protein microarrays
inTrODUcTiOn
Anti-cytokine autoantibodies (ACAAs) have been described in a growing number of immunodefi-
ciencies (1, 2). Additionally, ACAAs have been identified in the serum of patients with autoimmune 
disease and healthy donors (3–6). However, the prevalence of ACAAs in many human diseases, and 
their contributions to phenotype, remain understudied.
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Human type I interferons (IFNs) are a cytokine family with 
antiviral activity whose members include 13 interferon-α (IFN-
α) proteins, IFN-β, and several poorly defined gene products 
(7). High titer ACAAs against IFN-α and other type I IFNs are 
strikingly specific to the disease autoimmune polyendocrine 
syndrome type I (APS-1), although they have also been described 
in the following rare conditions with varying penetrance: patients 
with thymoma, patients with hypomorphic RAG1 or RAG2 muta-
tions, and in a patient with an NFKB2 mutation (8–10). Although 
there is debate as to whether the 13 different IFN-α paralogs have 
discrete functions, APS-1 sera have been shown to bind and 
neutralize all tested IFN-α paralogs. In this paper, we will refer to 
the tested protein, IFN-α A, as simply IFN-α.
Autoimmune polyendocrine syndrome type I is caused by 
mutations in the gene autoimmune regulator (AIRE). AIRE is 
a transcriptional regulator, expressed predominantly in medul-
lary thymic epithelial cells, responsible for the expression of 
a broad array of peripheral tissue antigens (11, 12). Peripheral 
tissue antigens are presented to developing T cells in the thymus, 
and autoreactive T  cells with high affinity T  cell receptors are 
deleted (13). Thus, AIRE serves as a key gene in T cell negative 
selection. APS-1 patients mount autoantibodies to a variety of 
different antigens (14, 15), but why all APS-1 patients mount 
autoantibodies against type I IFNs with nearly 100% specificity 
is an enigma. The in vivo consequences of ACAAs against type I 
IFNs in APS-1 are equally unclear, as APS-1 patients do not suffer 
increased frequencies of viral infections. However, a recent study 
identified an inverse correlation between type I IFN ACAAs and 
the prevalence of type I diabetes (T1D) (16–18).
Adding to our knowledge of ACAAs in immunodeficiency, 
we recently discovered high titer type I IFN ACAAs in RAG1 
and RAG2 mutation-associated immunodeficiencies (10). Lower 
titer IFN-α ACAAs have also been described in systemic lupus 
erythematosus and at lower prevalence in healthy individuals 
(3–5). The prevalence, etiology, and function of ACAAs in many 
other primary immunodeficiencies remain to be defined.
Immunodysregulation polyendocrinopathy enteropathy 
X-linked (IPEX) is a severe X-linked primary immunodeficiency 
and autoimmune disease caused by loss of function mutations in 
the gene FOXP3 (19). Most patients present shortly after birth 
with fulminant autoimmunity, including most prominently auto-
immune enteropathy, T1D, and eczematous dermatitis. FOXP3 is 
a master regulator of T regulatory cells (Treg). In IPEX patients, 
T effector cells (Teff) can become activated in the absence of the 
tolerizing functions of Treg leading to autoimmunity (20). IPEX 
patients are treated with pharmacologic immunosuppression, 
and bone marrow transplant has shown benefit for a subset of 
patients (21). Gene therapy trials aimed at editing the defective 
FOXP3 locus are under development.
IPEX-specific autoantibodies against the peripheral autoanti-
gens, villin, and harmonin have been described (22). To address 
whether ACAAs are present in IPEX, we performed a proteomic 
screen for ACAAs using custom-designed protein microarrays 
in a small cohort of IPEX patients. We discovered IgG ACAAs 
against IFN-α in IPEX sera and confirmed their presence by 
immunoassay. We extended our studies to a larger cohort of 
patients with IPEX and IPEX-like disease and also found elevated 
levels of IFN-α ACAAs in post hoc analysis. To understand the 
function of these ACAAs, we performed in vitro blocking experi-
ments which demonstrate serum blocking activity correlating 
strongly with IFN-α ACAA titer. Last, we purified IgG from sera 
to formally demonstrate that serum blocking activity is contained 
in the IgG fraction. Taken together, these studies describe the first 
identification of ACAAs against type I IFNs in IPEX.
MaTerials anD MeThODs
Patients
Samples from the European cohort were collected with 
informed consent under an ethical IRB approved at the San 
Rafaelle Hospital in Milan, Italy. Samples from the Seattle cohort 
were either collected with informed consent or de-identified 
under ethical IRB-approved protocols at the Seattle Children’s 
Hospital, where they were deemed exempt from requiring 
informed consent. For patients who went on to receive stem 
cell transplant, samples were collected before transplant. Post-
transplant samples were processed when available, but excluded 
from the analysis. All APS-1 patients showed homozygous or 
compound heterozygous known or predicted pathologic muta-
tions in AIRE. For all IPEX patients, sequencing of FOXP3 
revealed the presence of a known loss of function mutation. 
IPEX-like patients were defined as infants or children with the 
onset of autoimmune enteropathy or T1D mellitus in addition 
to another autoimmune feature with normal FOXP3 sequencing. 
We excluded from our IPEX-like control group patients with 
an identifiable genetic defect, including mutations in CD25, 
STAT1, STAT3, LRBA, or CTLA-4. Polyautoimmunity patients 
included as controls were defined as infants or children with 
the onset in infancy of either (A) 2 autoimmune diseases plus 
autoimmune serology or family history, or (B) 3 autoimmune 
diseases. The European cohort consisted of 6 IPEX patients, 10 
IPEX-like patients, 15 healthy controls, 5 APS-1 patients, and 
24 polyautoimmunity patients. The Seattle cohort consisted of 
19 IPEX patients, 12 IPEX-like patients, 6 APS-1 patients, and 
9 healthy controls.
antigen Microarrays
Antigen microarrays were printed using a Bio-Rad ChipWriter 
Compact robotic microarrayer and ChipWriter Pro software. 24 
biomolecules were purchased from multiple vendors and printed 
in triplicate at dilutions of 200  µg/ml onto epoxysilane-coated 
glass slides (Schott #1064016). A complete list of molecules and 
their vendors can be found in Table S3 in Supplementary Material.
Arrays were first blocked in 7% fetal bovine serum (FBS) 
(Omega Scientific) in PBS plus 0.1% Tween (Sigma-Aldrich) 
(PBST) for 1 h at 4°C rocking, and then washed three times in 
PBST. Arrays were probed for 1 h with serum diluted 1:150 in 
30% FBS 1% PBST, rocking at 4°C. Arrays were subjected to three 
5 min washes in 1% PBST. Serum reactivity was detected using 
an Alexafluor 647-conjugated goat anti-human IgG secondary 
antibody (Jackson #109-605-098) diluted to 2.5 µg/ml in 30%FCS 
1% PBST for 45 min. Arrays were washed three times in PBST 
and dried under negative pressure.
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Arrays were scanned using an Agilent microarray scanner and 
images processed using GenePix 6 software. Mean fluorescence 
intensities (MFIs) for each antigen were calculated by taking the 
mean of median fluorescence intensity for each replicate feature 
of each antigen.
iFn-α acaa immunoassay
An indirect immunoassay was performed by coating Nunc 
MaxiSorp® plates (catalog #44-2404-21) with IFN-α A (PBL, 
catalog #11101) at 1  µg/ml in PBS, blocking with 30% FBS in 
PBST, probing with serum diluted 1:100 in 5% FBS in PBST, and 
detecting with anti-human reagents purchased from Delfia per 
protocol (catalog #1244-330, www.perkinelmer.com).
igg Purification
IgG purification was performed using Pierce Protein G Spin kit 
per protocol (Thermoscientific #89949).
iFn-α Blocking assay
Frozen peripheral blood mononuclear cells from a healthy donor 
were thawed and 5 × 105 live cells were aliquoted into polysterene 
tubes (BD #352052) in 100 µl of RPMI 1640 medium with 10% FCS 
and 1% penicillin-streptomycin (Gibco #15070063) and incubated 
at 37°C for 2 h. 11 µl of either serum or medium were added to 
tubes, which were vortexed and incubated for 15 min. Cells were 
stimulated with IFN-α A (PBL #11102-2) in a 10 ul aliquot to tubes 
for a final concentration of 103 Units/ml. Cells were incubated for 
15 min, then promptly fixed for 10 min with parafaormaldehyde 
at final concentration of 1.5% (Electron Microscopy Sciences 
#15710) at room temperature. Cells were then permeabilized with 
cold methanol at 4°C for 20 min and then washed in cold PBS. Cells 
were stained with the following antibodies: BV421 mouse anti-
human CD3 (BD #562426), PerCP-Cy5.5 mouse anti-human CD4 
(BD #341654), and PE Mouse Anti-STAT1 (pY701) (BD #612564). 
Cells were washed and data acquired on an LSR II cytometer (BD). 
For each blocking experiment, percent of cells in the pSTAT1 gate 
was normalized to set the highest percentage as 100% by dividing 
all samples by the percentage of the highest sample.
statistical analysis
Heat maps were generated and significance analysis of microarrays 
(SAM) performed using the free software Multiple Experiment 
Viewer (23, 24). SAM false discovery rates (FDR) were set to 
<0.001.
Indirect immunoassay results were tested for statistical sig-
nificance using the Mann–Whitney test. Correlations between 
microarray and immunoassay data, and between microarray 
and blocking data, were performed using a quadratic non-
linear regression and linear regression, respectively, using Prism 
(Graphpad) software. Statistical significance of differences in 
blocking activity was calculated using an unpaired t-test.
resUlTs
antigen Microarrays identify acaas
Anti-cytokine autoantibodies are prominent in APS-1, which 
is caused by mutations in AIRE, a master regulator of T cell 
central tolerance. We hypothesized that ACAAs would also be 
a feature of IPEX, caused by mutations in FOXP3, a master 
regulator of Treg, as IPEX patients have defects in peripheral 
T cell tolerance. We studied 6 patients with IPEX, 10 patients 
with IPEX-like disease, 24 patients with polyautoimmunity, 
and 5 patients with APS-1. The clinical characteristics of IPEX 
patients in this cohort included diverse manifestations of auto-
immunity and immunodeficiency (Table S1 in Supplementary 
Material).
To discover novel ACAAs in primary immunodeficiencies 
and autoimmune diseases, we designed and fabricated protein 
microarrays with features, including cytokines, chemokines, 
growth factors, anti-microbial proteins, traditional autoantigens, 
and other biomolecules. After screening for autoantibodies in 
cohorts of other primary immunodeficiency patients, we selected 
24 of the most promising candidate antigens and printed targeted 
protein microarrays for the study of IPEX patients. Microarrays 
were probed with diluted serum, scanned, and analyzed (Table S4 
in Supplementary Material).
As expected, high reactivity autoantibodies against the type 
I IFNs; IFN-ω and IFN-α A (hereafter referred to as IFN-α); 
were detected in all APS-1 patients (Figure S1 in Supplementary 
Material). Serum derived from most, but not all APS-1 patients 
contained ACAAs against IL-17A and IL-17F, consistent with 
previously reported frequencies (25, 26). High and mid-range 
reactivity against the type III IFNs IL-28A and IL-28B were also 
observed in two patients. Our group and others have observed 
type III IFN ACAAs in small subsets of patients and in healthy 
individuals (unpublished observations J.M.R.). Autoantibodies 
against the traditional autoantigen thyroid peroxidase were also 
observed throughout the cohort and were most frequently found 
in patients with polyautoimmunity.
To identify autoantibodies unique to IPEX, we compared 
autoantibody levels between samples from IPEX and IPEX-like 
patients. After performing two-class SAM, we found statisti-
cally significant elevated levels of autoantibodies against IFN-α, 
IFN-ω, and IL-17A in IPEX samples as compared to IPEX-like 
samples (FDR < 0.001) (Figure 1A). ACAAs against IFN-α were 
of medium intensity compared to ACAAs in sera from APS-1 
patients, while those against IFN-ω and IL-17A were low, all 
below 10,000 units MFI. To confirm differences between healthy 
controls as well, we also compared autoantibody levels between 
samples from IPEX and healthy controls and found the same 
three ACAAs statistically elevated (FDR < 0.001), in addition 
to seven other autoantibodies. Since lower intensity ACAAs 
are less likely to have clinical significance, and given the known 
association of IFN-α ACAAs in APS-1, we focused further 
experiments on the role of IFN-α ACAAs in IPEX. We did not 
test for reactivity against the 12 other IFN-α paralogs, but in 
APS-1 high levels of cross-reactivity to the paralogs have been 
demonstrated (9).
Interferon-α and IFN-ω ACAAs were found across a range of 
MFIs in IPEX samples, but all were at levels lower than those 
found in APS-1 (Figure 1B). We validated IFN-α ACAA microar-
ray results by indirect immunoassay (p = 0.030) (Figure 1C). We 
correlated results between the two platforms and found highly 
significant correlation with r2 = 0.926 (Figure 1D).
A B
C D
FigUre 1 | Antigen microarrays identify anti-cytokine autoantibodies (ACAAs). (a) Significance analysis of microarrays identifies ACAAs enriched in 
immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) compared to IPEX-like disease (IPL) (false discovery rates <0.001). (B) ACAA mean 
fluorescence intensity values against interferon-α (IFN-α) in all patients studied as measured by antigen microarray. (c) ACAA counts against IFN-α in all patients 
studied as measured by indirect immunoassay (p = 0.003 Mann–Whitney) (D) Correlation of IFN-α ACAA values as measured by microarray compared to indirect 
immunoassay (r2 = 0.924 using quadratic regression).
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Blocking activity of iFn-α acaas
To further investigate the functional activity of IFN-α ACAAs 
in IPEX, we tested sera from IPEX and control sera for IFN-α 
blocking activity in  vitro. We tested serum for blocking activ-
ity by measuring its ability to inhibit IFN-α-induced STAT1 
phosphorylation in heterologous CD4+ T cells (Figures 2A,B). 
As expected, sera from healthy donors had minimal blocking 
activity. Sera from APS-1 patients, which had the highest levels of 
IFN-α ACAAs, had very high blocking activity. Sera derived from 
IPEX patients, which had intermediate levels of IFN-α ACAAs, 
demonstrated intermediate levels of blocking.
To demonstrate that blocking activity was found in the immu-
noglobulin fraction, we purified IgG from serum samples using 
protein G beads. Purified IgG reproduced the same patterns of 
blocking activity compared to the sera from which they were 
derived (Figure 2C). Flow-through fractions of sera depleted of 
IgG lost their blocking activity (data not shown). These results 
demonstrate that the serum factor blocking IFN-α signaling 
in vitro is IgG immunoglobulin.
To understand the relationships between IFN-α ACAA titer and 
blocking activity, we correlated IFN-α ACAA MFI with in vitro 
blocking activity from the corresponding sample (Figure  2D). 
IFN-α ACAA MFI and blocking activity were highly statistically 
significantly correlated (r2 = 0.9246, p < 0.0001). Taken together, 
these results demonstrate that IFN-α ACAAs in IPEX are of the 
IgG class and block IFN-α in proportion to their binding activity.
iFn-α acaa levels in a second iPeX 
cohort
To expand our observations to a second cohort, we measured IFN-
α ACAAs in IPEX patients and IPEX-like patients without known 
causative mutations who were cared for at the Seattle Children’s 
Hospital. In the Seattle cohort, patients also had mutations in all 
four domains of FOXP3 (Table S2 in Supplementary Material). 
Samples and control sera were tested by indirect immunoassay for 
IFN-α reactivity as described in Section “Materials and Methods.” 
Only pre-transplant samples were included in our analysis.
When comparing all IPEX patients to IPEX-like patients, 
IPEX patients had higher levels of IFN-α ACAAs, but this dif-
ference did not reach statistical significance, p =  0.078 (Figure 
S2A in Supplementary Material). On further examination of this 
cohort, we noticed significant age differences between IPEX-like 
and IPEX groups (7.91 v. 0.71 median years of age), which may 
represent a source of confounding. To control for this difference, 
we performed a post hoc analysis, including only patients greater 
than 1 year of age. In this post hoc analysis, we found elevated 
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FigUre 2 | Blocking activity of interferon-α (IFN-α) ACAAs. (a) Aliquots of a healthy donor’s PBMCs were incubated with serum and either stimulated with IFN-α or 
left unstimulated. Representative flow cytometry plots measuring STAT1 phosphorlyation in CD4+ gated T cells are shown. (B) Percent of CD4+ T cells gated for 
STAT1 phosphorylation after IFN-α stimulation in the presence of healthy, IPEX, or autoimmune polyendocrine syndrome type I sera (p = 0.012) or (c) IgG purified 
from sera (p = 0.013). Unpaired t-test. (D) Correlation between IFN-α ACAA reactivity and blocking activity (p < 0.001, r2 = 0.925), linear regression.
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levels of IFN-α ACAAs in IPEX and this difference reached 
statistical significance (p = 0.007) (Figure S2B in Supplementary 
Material). We similarly compared IPEX patients to healthy 
controls. In the all ages group, there was no statistical difference 
between the groups (p = 0.530), and in the post hoc >1-year-old 
analysis, difference approached, but did not reach statistical sig-
nificance (p = 0.0745). Surprisingly, two healthy control samples 
had medium level IFN-α ACAAs which contributed to a decrease 
in statistical significance, and further clinical history on these two 
individuals could not be obtained.
Separately, in this experiment we tested sera from IPEX-like 
patients with known causative mutation. One patient with a 
heterozygous gain of function CTLA-4 mutations, a recently 
discovered cause of IPEX-like disease (27) had elevated IFN-α 
ACAAs when compared to IPEX-like patients without a known 
causative mutation. Similarly, five patients with STAT1 gain of 
function mutations, another cause of IPEX-like disease, also had 
elevated levels of IFN-α ACAAs (p = 0.0365). To our knowledge, 
these are the first reports of IFN-α ACAAs in patients with STAT1 
and CTLA-4 mutations. Given the small number of these patients 
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tested, these observations should be tested for reproducibility in 
larger cohorts.
correlates of iFn-α acaas
In the two cohorts, patients had mutations in each of FOXP3’s 
four domains: the N-terminal, zinc-finger, leucine zipper, and 
forkhead domains. Although the number of samples was small, 
we did not see correlation between mutations in each domain and 
IFN-α ACAA titer. In fact, in the European cohort the sample 
with the highest reactivity came from a patient with a mutation 
in the N-terminal domain, and the second highest sample came 
from a patient with a mutation in the C-terminal domain (Table 
S1 in Supplementary Material).
The clinical consequences of IFN-α ACAAs in vivo are poorly 
understood (10). Type I IFNs are critical for antiviral immunity, 
but APS-1 patients with IFN-α ACAA are not known to suffer 
from more frequent viral infections. To assess for a phenotype of 
IFN-α ACAAs in vivo, we studied correlations between clinical 
and molecular phenotypes. The severity and frequency of viral 
infections, such as cytomegalovirus, herpes simplex virus, and S. 
aureus infection were more frequent than in the general popula-
tion, but severity of opportunistic infection was not correlated 
with IFN-α ACAA titer (Tables S1 and S2 in Supplementary 
Material). There were no observed clinical infections after immu-
nization with routine live vaccines. We also correlated age with 
IFN-α ACAAs in each cohort, and these correlations were not 
statistically significant.
A recent study has identified an inverse correlation between 
type I IFN ACAAs and T1D in APS-1 (18). In our IPEX cohort, 
we did not observe the same correlation as T1D was present in 
patients with both high and low reactivity IFN-α ACAAs (Table 
S1 in Supplementary Material). However, our study may not be 
powered to detect such differences, and the levels of reactivity in 
IPEX are significantly lower than those seen in APS-1, so effects 
seen by Meyer et al. may not be seen at lower titers.
DiscUssiOn
These data taken together demonstrate that low titer IgG 
IFN-α ACAAs with blocking activity are a feature of IPEX. In 
a European cohort, we found elevated levels of IFN-α ACAAs 
in IPEX compared to both IPEX-like and healthy controls. In 
a second cohort from Seattle Children’s Hospital, we found 
elevated levels of IFN-α ACAAs in IPEX compared to IPEX-like 
patients in a post hoc analysis looking at children greater than 
1-year-old. However, we do note that in the Seattle cohort dif-
ferences between IPEX and all IPEX-like, and IPEX and healthy 
controls did not reach statistical significance. The lack of statisti-
cally significant difference between IPEX and healthy controls in 
this cohort may be due to unexpectedly elevated levels of IFN-α 
ACAAs in the healthy control group, which may represent ran-
dom variation in the healthy population or undiagnosed disease. 
Given these findings, it will be informative going forward to test 
for reproducibility in other prospective cohorts of IPEX patients 
with both sufficient IPEX-like and healthy controls.
High titer IFN-α ACAAs are found in all patients with APS-1, 
which is caused by mutations in AIRE. Recent work has shown 
that high-titer type I IFN ACAAs are also found in most patients 
with RAG-mutation-associated primary immunodeficiency 
and in some cases of thymoma (10, 28). In both thymoma 
and immunodeficiency caused by RAG1 or RAG2 mutations, 
thymic deficiency of AIRE has been documented. This supports 
a unifying model, whereby defects in thymic AIRE expression 
are sufficient to generate type I IFN ACAAs at high titer and 
possibly complete penetrance (29). In contrast, less frequent and 
lower titer type I IFN ACAAs have been described in systemic 
lupus erythematosus, a complex disease characterized by defects 
in both central and peripheral tolerance (3–5, 30). Similarly, in 
IPEX, a disease with defects of peripheral T  cell tolerance, we 
now report ACAAs at lower titers than found in APS-1.
AIRE is the best described regulator of the central T  cell 
tolerance checkpoint. Similarly, FOXP3 is required for peripheral 
T  cell tolerance as a master regulator of Treg (31). Treg can also 
develop and reside in the thymus, so although IPEX’s major 
defect is that of peripheral tolerance, there may be a minor defect 
in central tolerance as well. These genes are mutated in APS-1 
and IPEX, respectively. These genetic diseases, as experiments of 
nature, allow us to localize defects in immune tolerance. Using the 
development of IFN-α ACAAs as one measure of autoimmunity, 
our results suggest a model with a necessary role for central T cell 
tolerance and an important, but non-essential role for peripheral 
T  cell tolerance. Our human studies are particularly revealing 
as type I IFN ACAAs are not observed in the murine model of 
APS-1 (32).
Two vexing questions remain. First, why are autoantibod-
ies generated against such a specific target? AIRE activates 
the transcription of a panoply of peripheral tissue antigens 
[although in the mouse IFN-α is not among them (33)], so the 
reason why type I IFNs are so exquisitely targeted is not obvious. 
One possibility is that IFN-α is specifically targeted because of 
its high level of inducibility and expression in inflamed tissue. 
IFN-α is expressed by the large majority of cell types and tissues 
(ProteinAtlas.org and BioGPS.org), and in the thymus, 35% of 
dendritic cells are plasmacytoid dendritic cells, major producers 
of type I IFNs. Patients with IPEX have a failure of tolerance 
which leads to inflammation and enteropathy, and indeed this 
inflammation may cause higher levels of IFN-α. In normal states 
of immune tolerance, T cells with high affinity interactions to 
IFN-α epitopes would be expected to be deleted by negative 
selection. However, in organisms with defects of tolerance, high 
local IFN-α concentrations could trigger an autoimmunization 
event (17). Such an immunization event is most likely to occur 
in the context of a viral infection, during which plasmacytoid 
dendritic cells secrete large amounts of type I IFN locally and 
systemically. In support of a viral trigger, we previously found 
an association between past Varicella infection and the develop-
ment of IFN-α ACAAs in patients with RAG deficiency (10). Our 
studies support such a model where defects in either central or 
peripheral tolerance can lead to failure to prevent IFN-α ACAAs, 
and tolerance to type I IFNs is maintained in a delicate balance 
by multiple checkpoints, each vulnerable to breach.
The second major remaining question is, what, if any, is the 
in vivo function or phenotype of these ACAAs, and are they help-
ful, harmful, or irrelevant to the host. In mice, genetic deficiency 
7Rosenberg et al. Neutralizing ACAAs Against IFN-α in IPEX
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 544
or passive transfer of blocking antibodies against type I IFNs 
increase susceptibility to viral infection (7, 34). However, APS-1 
patients, although susceptible to Candida infection, have not been 
found to be more susceptible to viral infections (16). Similarly, 
in SLE patients, no major clinical or serological differences were 
observed between patients with or without IFN-α ACAAs (4). In 
our study, after analyzing clinical, cellular, and molecular data, 
we did not observe a correlation between IFN-α ACAAs and 
increased rates of viral infection.
Recent results of multiple phase II randomized placebo con-
trolled trials utilizing IFN-α blockade for the treatment of SLE 
are germane to the question of the in vivo effect of IFN-α ACAAs 
(35, 36) (Astrazeneca ACR 2015). In all three trials, serious 
adverse events were similar between treated and placebo groups. 
However, all three trials showed increased rates of Varicella 
zoster reactivation in patients with IFN-α blockade. These results 
provide evidence that IFN-α ACAAs may increase the risk of viral 
infection, particularly Varicella zoster reactivation.
In summary, we have found elevated levels of IFN-α IgG 
blocking ACAAs in IPEX patients. These studies add to a litera-
ture of diseases in which IFN-α ACAAs have been described. The 
discovery of type I IFN ACAAs in IPEX, an experiment of nature, 
aids in the localization of defective tolerance checkpoints involved 
in the generation of type I IFN ACAAs. Their prevalence across 
immunological diseases demonstrates a primary importance for 
central T cell tolerance and a secondary role for peripheral T cell 
tolerance in preventing these ACAAs. Furthermore, given their 
prevalence in APS-1, RAG1/RAG2-associated immunodeficien-
cies, SLE, and now IPEX, it will be important to consider type 
I IFN ACAAs as potential diagnostics and biomarkers both in 
immunodeficiency and autoimmunity.
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FigUre s1 | Total antigen microarray data. Anti-cytokine autoantibodies mean 
fluorescence intensity from total array data are represented in heat map format 
with samples along the x-axis and antigens along the y-axis.
FigUre s2 | (a) Interferon-α ACAA levels in a second immunodysregulation 
polyendocrinopathy enteropathy X-linked cohort from Seattle, Washington as 
measured by indirect immunoassay including all samples and (B) post hoc 
analysis including only samples >1-year-old.
TaBle s1 | Immunodysregulation polyendocrinopathy enteropathy X-linked 
European Cohort Clinical and Laboratory Characteristics. Abbreviations: IS, 
immunosuppression; T1D, type I diabetes; HSCT, hematopoietic stem cell 
transplantation; ITP, immune thrombocytopenic purpura; CMV, cytomegalovirus; 
HSV, herpes simplex virus.
TaBle s2 | Immunodysregulation polyendocrinopathy enteropathy X-linked 
Seattle Cohort Clinical and Laboratory Characteristics.
TaBle s3 | Antigen vendors.
TaBle s4 | Protein microarray raw data.
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